Brugada syndrome

• Verfasst von: Antzelevitch, Charles [VerfasserIn]
• Verfasst von: Patocskai, Bence [VerfasserIn]
• Titel: Brugada syndrome
• Titelzusatz: clinical, genetic, molecular, cellular, and ionic aspects
• Verf.angabe: Charles Antzelevitch, PhD, FACC, FAHA, FHRS, and Bence Patocskai, MD
• E-Jahr: 2016
• Jahr: January 2016
• Umfang: 51 S.
• Teil: volume:41
• Teil: year:2016
• Teil: number:1
• Teil: pages:7-57
• Teil: extent:51
• Fussnoten: Gesehen am 09.01.2019
• Titel Quelle: Enthalten in: Current problems in cardiology
• Ort Quelle: Chicago, Ill. : Yearbook Medical Publ., 1976
• Jahr Quelle: 2016
• Band/Heft Quelle: 41(2016), 1, Seite 7-57
• ISSN Quelle: 1535-6280
• DOI: doi:10.1016/j.cpcardiol.2015.06.002
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1586079433

Abstract

Brugada syndrome (BrS) is an inherited cardiac arrhythmia syndrome first described as a new clinical entity in 1992. Electrocardiographically characterized by distinct coved type ST segment elevation in the right-precordial leads, the syndrome is associated with a high risk for sudden cardiac death in young adults, and less frequently in infants and children. The electrocardiographic manifestations of BrS are often concealed and may be unmasked or aggravated by sodium channel blockers, a febrile state, vagotonic agents, as well as by tricyclic and tetracyclic antidepressants. An implantable cardioverter defibrillator is the most widely accepted approach to therapy. Pharmacologic therapy is designed to produce an inward shift in the balance of currents active during the early phases of the right ventricular action potential (AP) and can be used to abort electrical storms or as an adjunct or alternative to device therapy when use of an implantable cardioverter defibrillator is not possible. Isoproterenol, cilostazol, and milrinone boost calcium channel current and drugs like quinidine, bepridil, and the Chinese herb extract Wenxin Keli inhibit the transient outward current, acting to diminish the AP notch and thus to suppress the substrate and trigger for ventricular tachycardia or fibrillation. Radiofrequency ablation of the right ventricular outflow tract epicardium of patients with BrS has recently been shown to reduce arrhythmia vulnerability and the electrocardiographic manifestation of the disease, presumably by destroying the cells with more prominent AP notch. This review provides an overview of the clinical, genetic, molecular, and cellular aspects of BrS as well as the approach to therapy.